Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress.

Business Wire • May 7, 2026

Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.

Zacks Investment Research • May 7, 2026

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right.

Business Wire • Mar 30, 2026

Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance

Aurinia Pharmaceuticals has undergone a major management overhaul, with fund manager and activist investor Kevin Tang appointed as the CEO. AUPH's COO and CFO have also been replaced. Lupkynis's net product sales reached $271.3M in 2025, up 25.5% YoY, with 2026 guidance for $305M–$315M, possibly conservative given the company's previous beat of initial 2025 guidance. Aritinercept will be evaluated in two autoimmune diseases, with one clinical study already underway and another set to commence in H1 2026, although the exact indications have not been disclosed.

Seeking Alpha • Mar 27, 2026

Mutiny At Aurinia Pharmaceuticals? Biotech Soars On C-Suite Shake-Up.

Aurinia Pharmaceuticals announced a complete overhaul of its C-suite on Monday, sparking both the biotech stock and hopes of an acquisition.

Investors Business Daily • Mar 23, 2026

Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning

The company said Kevin Tang, Aurinia's chair of the board, will succeed Peter Greenleaf as CEO, while Greenleaf will remain on as a consultant to support the transition.

Benzinga • Mar 23, 2026

Aurinia Announces Management Transition

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Management Transition.

Business Wire • Mar 23, 2026

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the following statement in response to the Company's announcement that Kevin Tang has been appointed Chief Executive Officer, effective immediately. Antoine Khalife, Founder of MKT Capital, stated: “Today marks a watershed moment for Aurinia shareholders. Since 2019,.

Business Wire • Mar 23, 2026

Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading lower Thursday afternoon after the lupus-focused drugmaker posted fourth quarter earnings and raised expectations for continued growth in 2026.

Benzinga • Feb 26, 2026

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026